OUTPERFORM:For the twelve months ahead, we see a reasonable valuation range between SEK220-240 per share suggesting 24-35% upside to the current share price. For 2020, we see a range between SEK270-300 per share suggesting 52-69% upside to the current share price.
For the first time, test results with new blood, and across all risk groups. Recent news flow from Immunovia has been intense and will continue to be intense in the coming quarters. The news about the last phase of the IMMray PanCan-d optimisation was important for particularly two reasons, we believe. First, the optimisation that was based on 937 blood samples included freshly collected blood, which compares with earlier trials that have been based on blood bank samples. Second, the samples were from individuals with a broad range of symptoms of pancreatic disease, reflecting a real-life commercial setting for the product.